MC4R — the appetite rheostat

Tissue

Hypothalamus & wider CNS

Ligands

α-MSH (agonist); AgRP (inverse agonist)

Function

The central rheostat of appetite and body weight — and the target of the anti-obesity agent setmelanotide.

When it fails

The most common monogenic cause of severe early-onset obesity in humans.

Of the five melanocortin receptors, MC4R is the one most directly tied to a common human disease. Expressed almost entirely in the central nervous system — densely in the paraventricular nucleus (PVN) of the hypothalamus — it is the point where the brain converts a hormonal read-out of the body's energy stores into the decision to eat or to stop.^[1]

The leptin–melanocortin circuit

MC4R sits at the business end of one of the body's best-understood appetite pathways. When fat stores are full, adipose tissue releases leptin, which crosses into the brain and acts on two opposing neuron populations in the arcuate nucleus:^[2]

• POMC neurons, which leptin activates — releasing α-MSH that travels to the PVN and switches MC4R on, suppressing appetite and raising energy expenditure.
• AgRP/NPY neurons, which leptin inhibits — these release agouti-related peptide, an inverse agonist that drives MC4R activity below baseline and promotes feeding.

Appetite, in other words, is set by a tug-of-war between α-MSH and AgRP at this one receptor. Like its relatives, MC4R couples to the stimulatory G-protein Gs and signals through cyclic AMP when activated.^[1] Because the whole chain — leptin → leptin receptor → POMC → α-MSH → MC4R — is a relay, a break at any link produces a similar phenotype of relentless hunger.

When it fails: monogenic obesity

Loss-of-function mutations in MC4R cause early-onset obesity with hyperphagia, and collectively they are the most common monogenic form of obesity — reported in the order of a few percent of people with severe, childhood-onset obesity, though exact estimates vary by population and ascertainment.^[3]Mutations further upstream — in leptin (LEP), the leptin receptor (LEPR), POMC, or the processing enzyme PCSK1 — converge on the same pathway and produce overlapping syndromes.^[2] This same circuit is where the GLP-1 weight drugs act — seeGLP-1 drugs and the appetite system.

Setmelanotide: refilling the signal

The therapeutic logic is direct: if the problem is too little MC4R activity, supply an agonist. Setmelanotide (marketed as Imcivree) is an MC4R agonist that works best when the receptor itself is intact but its upstream input is missing — which is why its clearest benefit is in deficiencies of POMC, PCSK1, and LEPR rather than in obesity caused by MC4R mutations themselves.^[4]

It was first approved by the FDA in November 2020 for obesity due to POMC, PCSK1, or LEPR deficiency, extended in 2022 to Bardet–Biedl syndrome, and in 2026 to acquired hypothalamic obesity.^[4] Dosing and eligibility are clinical decisions; this page describes mechanism, not treatment. See thetherapeutics section for the full profile.

Beyond appetite

MC4R is not only about hunger. The same receptor contributes to energy expenditure, glucose and insulin handling, blood-pressure regulation, and erectile function — which is both why melanocortin agents have cardiovascular considerations and why the pathway is studied well beyond obesity.^[1] For how MC4R fits the wider system, see theoverview pillar.

← Back to all receptors

Common questions

What does the MC4R receptor do?+

MC4R is the brain’s central control of appetite and body weight: when α-MSH activates it, you feel full and energy expenditure rises. The same receptor also influences blood pressure and sexual function.

What is MC4R deficiency?+

Loss-of-function mutations in MC4R cause early-onset obesity with intense hunger (hyperphagia). Collectively they are the most common single-gene (monogenic) cause of severe obesity in humans.

Can MC4R be targeted for weight loss?+

Yes. The MC4R agonist setmelanotide is approved for certain rare genetic and acquired hypothalamic obesity. Conversely, blocking MC4R is being studied to treat wasting (cachexia) — the same receptor, used in opposite directions.

References

1. 1.Cone RD. Studies on the physiological functions of the melanocortin system. Endocr Rev. 27(7):736–49. 2006. link ↗
2. 2.Yeo GSH, et al. The melanocortin-4 receptor pathway and the emergence of precision medicine in obesity management. Review (PMC11893075). 2025. link ↗
3. 3.Collet T-H, et al. Melanocortin 4 receptor pathway dysfunction in obesity: patient stratification aimed at MC4R agonist treatment. J Clin Endocrinol Metab. 103(7):2601–12. 2018. link ↗
4. 4.StatPearls. Setmelanotide. NCBI Bookshelf (NBK589641). 2024. link ↗